Named on 4 rounds in the feed, most often at Series A and in Biotech.
Rounds from 2024-06-11 to 2026-09-29
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AnaCardio A clinical-stage biopharmaceutical company developing novel therapies for heart failure | Series B Verified against 1 of 17 sources | $71.0M | 2026-09-29 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Series A Verified against 1 of 3 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $122.3M | 2025-10-16 | [ PART ] |
Callio Therapeutics Dual-payload antibody-drug conjugates (ADCs) for cancer treatment. | Series A Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $187M | 2025-03-03 | [ PART ] |
ADCytherix Adcytherix is a biopharmaceutical company focused on the development of novel antibody drug conjugates (ADC) to treat high unmet need diseases such as cancer. | Seed Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $32.2M | 2024-06-11 | [ PART ] |